Literature DB >> 20067707

Strategies to prolong the intravaginal residence time of drug delivery systems.

Esra Baloglu1, Zeynep Ay Senyigit, Sinem Y Karavana, Andreas Bernkop-Schnürch.   

Abstract

The vagina has been studied as a favorable site for local and systemic delivery of drugs for female-related conditions. There are a large number of vaginal medications on the market and most of them require frequent application due to their short vaginal residence time. A prolonged vaginal residence time of formulations is therefore a key parameter for improved therapeutic efficacy. Promising approaches to prolong the residence time base on mucoadhesion, in- situ sol-gel transition and mechanical fixation. Mucoadhesive drug delivery systems can be tailored to adhere to the vaginal tissue. In-situ gelling systems offer the advantage of increased viscosity in vaginal cavity and consequently reduce outflow from the vagina. Mechanical fixation needs specially shaped drug delivery systems and reduce the frequency of administration significantly. Within this review an overview on these different strategies and systems is provided. Furthermore, the techniques to evaluate the potential of these systems for prolonged vaginal residence time are described.

Mesh:

Year:  2009        PMID: 20067707     DOI: 10.18433/j3hp41

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  21 in total

1.  Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.

Authors:  Simi Gunaseelan; Philippe A Gallay; Michael D Bobardt; Charlene S Dezzutti; Timothy Esch; Richard Maskiewicz
Journal:  Pharm Res       Date:  2012-06-27       Impact factor: 4.200

2.  Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention.

Authors:  Jianing Meng; Tao Zhang; Vivek Agrahari; Miezan J Ezoulin; Bi-Botti C Youan
Journal:  Nanomedicine (Lond)       Date:  2014-01-10       Impact factor: 5.307

3.  Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion.

Authors:  Jianing Meng; Timothy F Sturgis; Bi-Botti C Youan
Journal:  Eur J Pharm Sci       Date:  2011-06-17       Impact factor: 4.384

4.  Long lasting mucoadhesive membrane based on alginate and chitosan for intravaginal drug delivery.

Authors:  Fabio Tentor; Giorgia Siccardi; Pasquale Sacco; Danilo Demarchi; Eleonora Marsich; Kristoffer Almdal; Sanjukta Bose Goswami; Anja Boisen
Journal:  J Mater Sci Mater Med       Date:  2020-02-14       Impact factor: 3.896

5.  20S Proteasome as a Drug Target in Trichomonas vaginalis.

Authors:  Anthony J O'Donoghue; Betsaida Bibo-Verdugo; Yukiko Miyamoto; Steven C Wang; Justin Z Yang; Douglas E Zuill; Shoun Matsuka; Zhenze Jiang; Jehad Almaliti; Conor R Caffrey; William H Gerwick; Lars Eckmann
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 6.  The importance of the vaginal delivery route for antiretrovirals in HIV prevention.

Authors:  Lindsay M Ferguson; Lisa Cencia Rohan
Journal:  Ther Deliv       Date:  2011-12

7.  Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.

Authors:  Claire J Forbes; Clare F McCoy; Diarmaid J Murphy; A David Woolfson; John P Moore; Abbey Evans; Robin J Shattock; R Karl Malcolm
Journal:  J Pharm Sci       Date:  2014-03-01       Impact factor: 3.534

8.  Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis.

Authors:  Priya Srinivasan; Jining Zhang; Amy Martin; Kristin Kelley; Janet M McNicholl; Robert W Buckheit; James M Smith; Anthony S Ham
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

9.  Nano- and microfabrication for overcoming drug delivery challenges.

Authors:  Kimberly R Kam; Tejal A Desai
Journal:  J Mater Chem B       Date:  2013       Impact factor: 6.331

10.  Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile.

Authors:  Sanjida Mahjabeen; Manolya Kukut Hatipoglu; Stanley D Kosanke; David Garcia-Contreras; Doris M Benbrook; Lucila Garcia-Contreras
Journal:  J Pharm Sci       Date:  2020-02-27       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.